Moloney Securities Asset Management LLC bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, Holdings Channel reports. The fund bought 29,714 shares of the biopharmaceutical company’s stock, valued at approximately $1,736,000. Bristol-Myers Squibb makes up approximately 1.0% of Moloney Securities Asset Management LLC’s investment portfolio, making the stock its 20th largest position.
A number of other large investors have also added to or reduced their stakes in the company. Guild Investment Management Inc. acquired a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $3,754,000. Gillespie Robinson & Grimm Inc. raised its position in shares of Bristol-Myers Squibb by 24.4% in the third quarter. Gillespie Robinson & Grimm Inc. now owns 6,371 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 1,250 shares during the last quarter. Jacobs & Co. CA raised its position in shares of Bristol-Myers Squibb by 105.9% in the third quarter. Jacobs & Co. CA now owns 48,138 shares of the biopharmaceutical company’s stock valued at $2,595,000 after buying an additional 24,754 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Bristol-Myers Squibb by 0.3% in the third quarter. Fisher Asset Management LLC now owns 650,332 shares of the biopharmaceutical company’s stock valued at $35,066,000 after buying an additional 2,225 shares during the last quarter. Finally, Naples Global Advisors LLC raised its position in shares of Bristol-Myers Squibb by 26.5% in the third quarter. Naples Global Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $1,029,000 after buying an additional 4,000 shares during the last quarter. 69.67% of the stock is owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at 56.04 on Tuesday. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $77.12. The company has a market capitalization of $93.74 billion, a price-to-earnings ratio of 21.15 and a beta of 1.00. The company’s 50-day moving average price is $55.49 and its 200-day moving average price is $54.84.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.67 by $0.04. Bristol-Myers Squibb had a return on equity of 31.39% and a net margin of 22.94%. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the company posted $0.38 EPS. The firm’s revenue was up 22.3% on a year-over-year basis. On average, equities research analysts predict that Bristol-Myers Squibb Co will post $2.82 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 58.87%.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Mideast Time and is the property of of Mideast Time. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.mideasttime.com/moloney-securities-asset-management-llc-invests-1736000-in-bristol-myers-squibb-co-bmy/1590230.html.
Several research analysts have issued reports on BMY shares. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $56.28 price target on the stock. in a report on Monday, March 13th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $47.00 to $53.00 and gave the stock a “market perform” rating in a report on Monday, January 23rd. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, January 9th. Leerink Swann reiterated an “outperform” rating and issued a $62.00 price target on shares of Bristol-Myers Squibb in a report on Monday, January 30th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $66.00 price target (down previously from $69.00) on shares of Bristol-Myers Squibb in a report on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $61.83.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 92,405 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $57.02, for a total transaction of $5,268,933.10. Following the transaction, the executive vice president now owns 488,063 shares in the company, valued at approximately $27,829,352.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph C. Caldarella sold 8,096 shares of the company’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $57.29, for a total value of $463,819.84. Following the transaction, the senior vice president now owns 55,637 shares in the company, valued at approximately $3,187,443.73. The disclosure for this sale can be found here. Insiders have sold a total of 105,501 shares of company stock worth $6,015,203 in the last quarter. Company insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.